Your Trusted Brand for Over 35 Years

Daily News

Research and Markets: EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022 - Social Stigmas Prove Challenge

Business Wire


DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the "EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022" report to their offering.

Social Stigmas Prove Challenge to Vaginal Atrophy Sufferers

This report provides an overview of the risk factors and global trends of postmenopausal vaginal atrophy in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan). It includes a 10-year epidemiology forecast of PVA prevalent cases segmented by age (in five-year increments beginning at 50 years and ending at 79 years) and severity (mild, moderate, and severe) in the 7MM.

Cultural and social modesty is leaving women uncomfortable discussing Postmenopausal Vaginal Atrophy (PVA) - a condition which goes underdiagnosed worldwide, states a new report by research and consulting firm The authors.

This new report found that up to 50% of postmenopausal women experience symptoms of vaginal atrophy, but only a quarter of these individuals seek medical treatment, and cultural and social attitudes toward sexuality and aging play a huge role in this.

The urogenital tract, including the vagina, bladder and pelvic floor muscles, contains estrogen receptors, and so estrogen depletion causes deterioration of tissues and discomfort in this area. PVA causes vasomotor symptoms, including hot flushes, night sweats and mood swings, and urogenital symptoms, such as vaginal discomfort, pain during urination, and pain during sexual intercourse. While vasomotor symptoms typically resolve over time, urogenital symptoms can remain a persistent problem.

Women may neglect to report PVA symptoms due to the assumption that they are an inevitable consequence of the aging process, or due to embarrassment stemming from cultural norms, as symptoms are closely associated with sexual function. Geographical patterns have been found in the prevalence of PVA, with women in the US more likely to discuss PVA symptoms with their doctor than European women, who are in turn far more likely to have open conversations about sexuality and menopause with their doctor than Japanese women. These differing tendencies in discussing personal matters with healthcare professionals dictate the rates of PVA diagnosis and treatment across countries.

During 2012, there were 31.56 million prevalent cases of PVA across the US, France, Germany, Italy, Spain, the UK, and Japan. The authors epidemiologists forecast that by 2022 there will be 36.14 million prevalent cases, showing an annual growth rate of 1.45%, as the global population continues to age.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Epidemiology

3.1 Risk Factors and Comorbidities

-- 3.1.1 Sexual inactivity increases symptoms of postmenopausal vaginal


-- 3.1.2 Smoking causes early menopause and exacerbates atrophic vaginal


-- 3.1.3 PVA prevalence is higher in women who have undergone cancer

treatment 3.2 Global Trends

3.3 Forecast Methodology

-- 3.3.1 Sources Used

-- 3.3.2 Forecast Assumptions and Methods

-- 3.3.3 Sources Not Used 3.4 Epidemiology Forecast of Postmenopausal Vaginal Atrophy

-- 3.4.1 Prevalent Cases of Postmenopausal Vaginal Atrophy

-- 3.4.2 Age-Specific Prevalent Cases of Postmenopausal Vaginal Atrophy

-- 3.4.3 Postmenopausal Vaginal Atrophy by Severity 3.5 Discussion

4 Appendix

For more information visit Research and Markets

Research and Markets Laura Wood, Senior Manager U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Women's Health

Source: Research and Markets

Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.